Luke O. Buchmann

Jane Porretta, M.D. is a board certified general surgeon specializing in breast surgery. She received her medical degree from Wayne State University in Detroit, MI graduating with honors. She completed her surgical training at the University of Utah School of Medicine. She is a fellow of the American College of Surgeons and is an active member of the American Society of Breast Surgeons. Dr. Porretta's focus is on the surgical treatment and diagnosis of breast cancer. She served as medical director of a community breast center before joining the Huntsman Cancer Institute breast cancer team. She practices techniques in breast cancer surgery for improved cosmetic outcomes including oncoplastic procedures in breast conservation and nipple and skin sparing mastectomies. She has additional training and certification in breast ultrasound and uses this in the clinic and operating room for diagnostic assistance and improved tumor localization. Since joining the University of Utah and the Huntsman Breast Surgery Group Dr. Porretta has expanded the surgery program in the South Jordan and Farmington Health Center facilities making access to advanced clinical care available to patients living in these communities. Dr. Porretta has been instrumental in bringing new techniques and technologies in breast surgery to the University of Utah/Huntsman facilities. She has supported clinical research enrolling patients in appropriate clinical trials from all Huntsman clinical locations. Though Dr. Porretta has a special interest in breast surgery, she has extensive experience in general surgery practice. She has been operating for over 25 years performing laparoscopic and open surgical procedures including gallbladder surgery, hernia repair, abdominal procedures, subcutaneous and soft tissue mass excision,lymph node surgery, and placement of intravenous access ports. Dr Porretta has a busy general surgery practice at the University's South Jordan Health Center.

Dr. Park is the chief for Pediatric Otolaryngology-HNS at the University of Utah and Primary Children's Hospital. He oversees the operations for the eight pediatric otolaryngology fellowship trained physicians and has had the privilege to treat children for over fifteen years at Primary Children’s hospital. His scope of practice includes a wide range of pediatric otolaryngology conditions that include cytomegalovirus infections, hearing loss, airway obstruction, congenital neck lesions, and recurrent parotitis to name a few. He was born in Baltimore, Maryland and raised in New Jersey. He attended Swarthmore College for his undergraduate studies then moved to St. Louis to obtain his medical degree at the Washington University School of Medicine. He subsequently completed his residency in otolaryngology at Loyola University Medical Center in Chicago and his fellowship in pediatric otolaryngology at the Hospital for Sick Children in Toronto, Canada. He joined the faculty at Loyola University Medical Center in Chicago for seven years. In August 2002, he moved to Salt Lake City to become an Associate Professor at the University of Utah. He is currently a professor and pediatric otolaryngologist (Ear Nose and Throat Specialist) at the University of Utah and at Primary Children’s Hospital. He is the principal investigator for an NIH funded multi-institutional clinical trial to determine whether the antiviral drug, valganciclovir can improve hearing outcomes for children with cytomegalovirus (CMV), a very common and understudied cause of childhood hearing loss. In fact, CMV is the most common infectious cause of pediatric sensorineural hearing loss. He also established a CMV working group comprising of pediatric genetics, infectious disease, otolaryngology, audiology, neurology, department of health (EHDI) and ARUP laboratories to streamline clinical and research initiatives in this field. These collaborative efforts have resulted in the first clinically validated dry blood spot and saliva PCR assay available to test any child for congenital CMV infection. He also worked with Representative Menlove and others to introduce a bill in the Utah legislature to increase overall awareness about congenital CMV infection and to mandate early CMV testing for newborns who fail their hearing screen. This legislation was passed in July 2013, and Utah became the first state to introduce a hearing targeted screening program for early CMV diagnosis. He has served on the Otolaryngology Otology study section for the American Academy of Otolaryngology – Head and Neck Surgery (AAO-HNS), as a reviewer for NIH and on several program committees for the AAO-HNS, the Triologic Society and American Society of Pediatric Otolaryngology (ASPO). He was the chair of the American Society of Pediatric Otolaryngology (ASPO) research committee and created the ASPO CMV network to foster pediatric multi-institutional clinical studies. He a board member of the National CMV Foundation, the only national organization established to inform and educate others on specific prevention measures to protect against the risk of CMV. https://healthcare.utah.edu/ent/specialties/pediatric-ent/cytomegalovirus.php He has lectured throughout the United States, Europe and, Asia on a wide range of pediatric otolaryngology and hearing related topics. He is the author of over 80 journal articles and book chapters and greatly enjoys teaching undergraduates, medical students, residents and fellows. He has been married for over 20 years, has two great kids and two wonderful dogs. He enjoys swimming and triathlons.

Dr. Slatnick is currently an assistant professor at the University of Utah School of Medicine in the division of Pediatric Hematology/Oncology. She is a member of the Solid Tumor team at the University of Utah and Primary Children’s Hospital. She received her medical degree from the University of Texas Southwestern Medical School. She completed her pediatric residency in Pediatrics at the University of Colorado School of Medicine. She also completed her fellowship in Pediatric Hematology-Oncology and MSCS degree in Clinical Sciences at the University of Colorado. Dr. Slatnick is board-certified by the American Board of Pediatrics and National Board of Medical Examiners. She is a member of many professional societies, including The American Academy of Pediatrics, Children's Oncology Group, The National Comprehensive Cancer Network (NCCN) Neuroblastoma Committee, The American Society of Clinical Oncology, The American Society of Hematology, and the Children’s Oncology Group. She has over 10 years of research experience. Dr. Slatnick’s clinical interests include all solid tumors with a specific interest in neuroblastoma therapy. Her primary research focuses on supportive care practices in immunocompromised patients, with a particular interest in infectious complications and antimicrobial management in the oncology patient population.